APLS

Apellis Pharmaceuticals, Inc.

—

$41.03

+0.00% today

last filing 2026-02-27Pro sees filings in ~15 min

Price

46 sells

Analyst consensus

Hold

$40.92target

$40.00 low today target$41.00 high

13 analysts · ~12-month consensus · as of Jul 10. Relayed analyst opinion, which tends to run optimistic — not our forecast or advice.

Earnings

Beat 3 of last 4

Earnings per share · actual vs forecast

Q2 '25+29.8%

−$0.33

exp −$0.47

Q3 '25+77.3%

$1.67

exp $0.94

Q4 '25-19.4%

−$0.47

exp −$0.39

Q1 '26

$0.15

exp −$0.36

Type	Date	Insider	Title	Of stake	Shares	Price	Value
Grant	2026-03-03	Dolsten Mikael	Director	—Direct	14,312	—	—
Sell	2026-02-13	DeLong Mark Jeffrey	Chief Business & Strat Officer	—Direct	368	$22.15	$8.2K
Exercise	2026-02-05	Francois Cedric	Chief Executive Officer	—Direct	8,840	$3.76	$33.2K
Grant	2026-01-30	Boucher Kelley	Chief People Officer	—Direct	30,146	—	—
Grant	2026-01-30	Chopas James George	VP/Chief Accounting Officer	—Direct	16,150	—	—

Grant

Dolsten Mikael

Director · 2026-03-03

—

14,312 shares

Sell

DeLong Mark Jeffrey

Chief Business & Strat Officer · 2026-02-13

$8.2K

368 @ $22.15

Exercise

Francois Cedric

Chief Executive Officer · 2026-02-05

$33.2K

8,840 @ $3.76

Grant

Boucher Kelley

Chief People Officer · 2026-01-30

—

30,146 shares

Grant

Chopas James George

VP/Chief Accounting Officer · 2026-01-30

—

16,150 shares

74 more transactions on ProFull insider transaction history is a Pro feature.

Upgrade →